News & Events


Bourne Partners and The Emerson Group Form Daybreak Consumer Care to Build Global Consumer Healthcare Company

March 5, 2020

WAYNE, P.A. & CHARLOTTE, N.C.–()–Bourne Partners, a healthcare-focused private equity investor and investment bank, is investing in a joint venture with The Emerson Group, an international consumer products equity organization, to build a global consumer health and wellness platform focused on acquiring and commercializing branded, over the counter (“OTC”) medications and personal care brands. This new venture, known as Daybreak Consumer Care (“Daybreak”), seeks to unite Bourne’s market expertise, product acquisition track record, and platform capabilities with The Emerson Group’s strategic relationships, substantial sector knowledge, and diverse value-added services for consumer companies. Daybreak will focus on acquiring other consumer healthcare companies and strategically-aligned brand portfolios. The combined track record and industry expertise of Bourne Partners and The Emerson Group provides a unique operating and investment platform.

“We value our relationship with Bourne Partners,” said Scott Emerson, President of The Emerson Group. “Bourne Partners has proven transactional experience across pharma and consumer health. Formalizing the relationship with Bourne is a reflection of our belief that the partnership can provide real solutions to consumers who need effective OTC treatments and desire high quality personal care products. We look forward to working with the Bourne team to build this company, deliver value to our retail partners and, most importantly, the end consumer.”

“We have known of The Emerson Group and its outstanding reputation for many years up and down the value chain. We have built a great relationship between two entrepreneurial organizations that will only continue to grow,” said Bourne’s Founder and CEO, Banks Bourne. “With Bourne’s transaction and investing expertise, coupled with Emerson’s world-class strategic brand activation capabilities, we believe Daybreak will have the opportunity to scale and execute to achieve our ambitious goals. Throughout our firm’s history, we have partnered with nearly all of Big Pharma as acquirers and stewards of legacy brands. Our goal with this new joint venture is to deploy up to $500 million or more of equity into this platform over time. We are excited to bid on companies and assets across the globe in combination with our domestic, international, and global partners.”

About The Emerson Group

The Emerson Group is a consumer products equity organization singularly focused on brands reaching maximum potential, who connects over-the-counter health and beauty brands to loyal shoppers. The Emerson Group specializes in strategic planning, category assessments, due diligence, acquisition, and feasibility studies. The Emerson Group also provides the efficient logistics infrastructure necessary to build brands, and offers data and shopper insights for making connections between brands and their target consumers. The Emerson Group leads the industry as a retail partner of choice and provides advanced analytical tools and research for proprietary insights. With over 25 years of experience, The Emerson Group is able to identify opportunities and activate plans that improve sales fundamentals and brand performance. The company was founded in 1996 and is based in Wayne, Pennsylvania. The Emerson Group has long-standing connections to a strong voice with major and regional retailers and is able to provide expertise, competency, and leadership in sales and support to retail partners and clients. They ensure over-the-counter health and beauty brands are given the attention they deserve. For more information, please visit

About Bourne Partners

Headquartered in Charlotte, N.C., Bourne Partners is a financial services firm specializing in the pharma, pharma services, OTC, and consumer health sectors. The firm offers investment banking and advisory services, and through Bourne Partners Strategic Capital (“BPSC”) sources and executes direct private equity investment transactions in Bourne’s key focus areas. As owners and operators with over 20 years of experience, BPSC has investment, strategic, and operational experience in companies ranging from $10mm to $3bn in equity value. In some companies, BPSC was the sole equity investor. In larger platforms including Covis Pharma, Millicent Pharma and PAI, BPSC partnered with Cerberus Capital Management, The Carlyle Group and Enhanced Healthcare, respectively. BPSC employees and partners invest a substantial amount of personal capital into each transaction to ensure true alignment of interests between investors, management and other stakeholders. BPSC seeks to add value to its partner companies and fund investments by applying its network of strategic relationships (both private equity and industry relationships), advisory and consulting expertise, and operating experience to generate a positive outcome for management, employees, and investors. For more information, please visit